BackRecro Pharma Overview

Recro Pharma Current Assets

Latest current assets for REPH: $53M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$53.46M
↓ 3.82% YoYΔ $-2.13M vs prior year quarter

Peer average

Loading

Recro Pharma Current Assets History

Loading

Recro Pharma vs. peers: Current Assets Comparison

Loading

Recro Pharma Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Recro Pharma (REPH) FAQ

As of the most recent data (December 2023), REPH shows a current assets of $53M. That compares with $56M in the prior-year period — down 3.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, REPH's current assets is now $53M (was $56M) — a 3.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Recro Pharma is outperforming or lagging.

Tracking REPH's current assets over time shows whether Recro Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $53M That compares with $56M in the prior-year period — down 3.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Recro Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $53M) with ownership activity and broader fundamentals.

Recro Pharma's current assets is $53M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.